Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
BioNexus Gene Lab Corp. logo

NASDAQ · BGLC

BioNexus Gene Lab Corp.

Healthcare · Medical - Diagnostics & Research

$1.29

Up+$0.04 (+3.20%)

Updated Oct 10, 2026, 8:11 AM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.51M
P/E ratio
-3.27
Dividend yield
0.00%
52-week range
$1.07 – $2.70
Volume
3.88K
Avg. volume
186.93K

Price performance · BGLC

BGLC price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

BGLC closed at $1.29 after 21 trading sessions, down 19.88% for the selected period.

Last close
$1.29
Period change
-19.88%
Period low
$1.20
Period high
$1.61
Daily close
View OHLC price history
BGLC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$1.2071$1.29$1.2071$1.293.88K
Oct 8, 2026$1.3258$1.3258$1.2493$1.24931.12K
Oct 7, 2026$1.33$1.3599$1.2055$1.3427.46K
Oct 6, 2026$1.21$1.27$1.20$1.2418.36K
Oct 5, 2026$1.28$1.31$1.2712$1.2812.85K
Oct 2, 2026$1.25$1.2778$1.25$1.272.95K
Oct 1, 2026$1.28$1.43$1.20$1.2040.81K
Sep 30, 2026$1.28$1.28$1.1601$1.229.57K
Sep 29, 2026$1.37$1.3984$1.27$1.2714.98K
Sep 28, 2026$1.3799$1.41$1.27$1.3011.5K
Sep 25, 2026$1.43$1.4699$1.2534$1.396.04K
Sep 24, 2026$1.4999$1.4999$1.44$1.483.11K
Sep 23, 2026$1.45$1.471$1.45$1.473.34K
Sep 22, 2026$1.475$1.48$1.45$1.462K
Sep 21, 2026$1.53$1.54$1.47$1.5010.74K
Sep 18, 2026$1.45$1.57$1.45$1.577.32K
Sep 17, 2026$1.46$1.49$1.46$1.4751.19K
Sep 16, 2026$1.57$1.57$1.45$1.484.83K
Sep 15, 2026$1.47$1.47$1.44$1.443.48K
Sep 14, 2026$1.4531$1.50$1.4465$1.501.65K
Sep 11, 2026$1.5372$1.61$1.5372$1.611.83K

Latest BGLC news

The latest Smart Investors Daily articles mentioning BGLC.

Stock researchCompany · Overview

BGLC research

Overview

Company profile and research snapshot.

Company profile

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 7, 2026

BioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI Licence

Licence of up to 20 years, payable in shares, as Malaysia commits RM1 billion to digitalizing public healthcareKUALA LUMPUR, Malaysia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("Company" or "BGLC") today announced plans to build AI applications for Malaysian healthcare, following the signing of a definitive agreement with Ruanyun Edai Technology Inc. (Nasdaq: RYET) on October 5, 2026 for an exclusive Malaysian healthcare licence to RYET's CogniAI artificial intell

Yahoo · Oct 5, 2026

RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab

License of up to 20 years and reciprocal share exchange would entitle RYET to a 10% royalty on qualifying technology receipts and 560,000 BGLC shares as Malaysia accelerates public healthcare digitalizationKUALA LUMPUR, Malaysia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ruanyun Edai Technology Inc. (NASDAQ: RYET) (“RYET” or the “Company”) today announced that it has signed a definitive agreement under which, on closing, RYET would grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) (“BGLC”) an exclusive licen

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By